Cure My Disease

Don't miss your cure!

 Log in / Sign up

Training the immune system to hunt down leftover liver cancer cells

NCT ID NCT06193733

Ongoing Prevention Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 2 trial tests whether a vaccine made from a patient's own dendritic cells — immune cells trained to recognize liver cancer — can prevent the cancer from returning after surgical removal of the tumor. About 74 adults with a high risk of recurrence will receive the vaccine as an add-on to standard care. The goal is to see if this personalized immunotherapy can improve disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a personalized dendritic cell vaccine made from the patient's own immune cells
What this could lead to
If successful, this approach could offer a way to reduce the high recurrence rate of liver cancer after surgery, potentially improving long-term survival.
What could go wrong
This is an early-phase trial with a small number of participants, so the vaccine may not prove effective. Side effects from immune activation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

  • Chang Gung Medical Foundation

    Taiyuan, Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.